<DOC>
	<DOCNO>NCT00673556</DOCNO>
	<brief_summary>To assess efficacy safety Alefacept compare placebo treatment Chronic Plaque Psoriasis patient conventional therapy ineffective inappropriate</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Alefacept Psoriasis Patients Whom Conventional Treatment Ineffective Inappropriate</brief_title>
	<detailed_description>Patients complete initial 24-week treatment course ( 12 week weekly dose follow b 12 week follow-up ) meet eligibility criterion continue 24-week open label extension</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Diagnosis Chronic Plaque Psoriasis involve ≥ 10 % body surface area Treatment history Psoriasis 3 conventional antipsoriatic therapy inappropriate ineffective CD4+ T lymphocyte count low limit normal Clinically significant abnormal hematology value blood chemistry value AST ALT ≥ 3x upper limit normal Other type Psoriasis Serious infection within 3 month prior first dose study drug History drug alcohol abuse within past 2 year Antibody positive HIV History malignancy History clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease Exposure psoriasismodifying phototherapy highpotency topical corticosteroid therapy within 2 week prior first dose study drug Exposure systemic antipsoriatic therapy , topical immunomodulators topical CNIs within 4 week prior first dose study drug Current treatment therapy tuberculosis Previous exposure Alefacept Nursing mother , pregnant woman , woman plan become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Chronic Plaque Psoriasis</keyword>
	<keyword>Alefacept</keyword>
</DOC>